Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II-study (Therapeutic Exploratory) of GAD-alum in Newly Diagnosed Type-1 Diabetic Patients, With Focus One the Presence of Viruses at the Time of Diagnosis

NCT01129232 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT01129232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01129232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II-study (Therapeutic Exploratory) of GAD-alum in Newly Diagnosed Type-1 Diabetic Patients, With Focus One the Presence of Viruses at the Time of Diagnosis
Lead sponsor
Oslo University Hospital
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2011
Completion date
January 31, 2013
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmunity, diabetes, type i, enterovirus infections